Buy or sell Abpro stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies

Abpro Stock
Abpro is a biotechnology company focused on therapeutics, diagnostics, and research.
About Abpro Stock
Abpro is a biotechnology company dedicated to accelerating biological research by providing superior tools to researchers worldwide. As a pioneer of industrial biochemistry and an emerging leader in the reagents field, they have developed a proprietary technology platform that allows for faster, more efficient production of recombinant proteins and antibodies. As a result, Abpro delivers superior quality products at industry-leading speeds. Abpro leveraging these platforms, both independently and through collaborations with global pharmaceutical companies and research institutions to develop therapeutic antibodies for use in immuno-oncology, ophthalmology, and other disease areas. The DiversImmune platform enables the generation of novel antibodies and next-generation antibody therapies.
Funding History
March 2016 | $12.4M |
---|---|
April 2017 | $10.0M |
January 2020 | $18.0M |
April 2022 | $2.0M |
Management
CEO & CO-FOUNDER
Eugene Cha
SVP OF STRATEGIC ALLIANCES
John Xu
Chairman & CEO
Ian Chan
CMO & SVP
Robert J. Markelewicz
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase